BioSpace News Archive

KEYTRUDA Now Approved for Patients With PD-L1-Positive Esophageal Squamous Cell Carcinoma Who Have Progressed After Chemotherapy and for a Six-Week Dosing Schedule Across All Adult Indications

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, announced that it has entered into a purchase and marketing agreement with Vantage Outsourcing for DEXYCU® 9%.

Orchard Therapeutics, a global gene therapy leader, announced presentations at the upcoming 46th Annual Meeting of the European Society for Blood and Marrow Transplantation, taking place virtually from August 29 - September 1, 2020.

TRV027 is a novel AT1 receptor selective agonist with the potential to treat acute lung damage / abnormal blood clotting associated with COVID-19

Medtronic plc announced that its Board of Directors appointed Kevin Lofton to the Board as an independent director, effective September 15, 2020.

This is the Company’s third FDA-cleared indication for its Deep TMS System, and is the first FDA clearance in the addiction space for any TMS device

Harbour BioMed, a global clinical-stage biopharmaceutical company announced that it has entered into a strategic collaboration with Vir Biotechnology, a clinical-stage immunology company, to discover, develop and commercialize potential novel therapeutic molecules in the fields of Immuno-Oncology and infectious diseases.

Transparency Market Research (TMR) has published a new report titled, ‘Dental Cements Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019-2027’.

According to the report, the global ornithine transcarbamylase (OTC) deficiency treatment market was valued at ~US$ 600 Mn in 2019.

Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announced the appointment of Michael Elliott, MBBS, PhD as Chief Scientific Officer.